Posts tagged “Novartis”
Novartis reportedly is in negotiations with fellow drug giant Merck about a $10 billion asset swap that would include the Novartis human vaccines and animal health businesses. Novartis operates a huge vaccine in Holly Springs and is building an R&D center in RTP.
Several technology and life science firms with a major presence in North Carolina crack the top 25 in the annual World's Best Multinational Workplaces ranking. NetApp, Cisco, Google, Microsoft and Novartis all make the list.
Employees rolled up their sleeves at the $1 billion Novartis Holly Springs vaccine manufacturing facility this week and joined the global throngs marking a revolution in the fight against flu.
Novartis, which operates a huge vaccine manufacturing facility in Holly Springs, is going to hire up to 100 people to staff a new research and development lab in Research Triangle Park. Some jobs also will be moved to RTP from Massachusetts.
International drug maker Novartis will start a strategic review of its units as early as next week and would consider a $10 billion purchase among options for bolstering the business, says new Chairman Joerg Reinhardt.
Europe's biggest drugmaker says it expects to lose $2.7 billion in sales to generic competition this year, 23 percent less than it previously forecast, as it continues to benefit from Ranbaxy Laboratories's failure to market a copycat version of the Diovan hypertension drug.
Several high-tech and life science firms based in North Carolina or who have a large presence here crack the "Best Multinationals" to work for list in Europe. But several of them also drop somewhat from the 2012 list.
Daniel Vasella, who is stepping down as chairman of international drug firm Novartis and decided not to accept a $78 million non-compete agreement, is now talking with the company about a consulting role.
As drug maker Novartis goes through a change at the top with Chairman Daniel Vasella stepping down, investors celebrate the move and call for the company to spin off some assets such as its vaccine business.
The U.S. Food and Drug Administration gives approval for a seasonal influenza vaccine produced at Novartis' new, huge production facility in Holly Springs.
Patients taking Novartis's QVA149 were able to expel more air from their lungs in one second than those receiving Glaxo's best-selling Advair after 26 weeks of treatment, according to a summary of data from a trial.
If successful, LCZ696 would be the first drug for patients with preserved ejection fraction, a condition in which the organ's ventricles still pump out more than 40 percent of the blood that comes in, but the atrium chamber fails to supply enough blood to the ventricle to meet the body's needs. The condition, which mainly affects women, accounts for about half of all heart failure patients.
Novartis along with Duke and NCSU will create a center for biodefense and to combat pandemic influenza in Holly Springs under a $60 million contract with the U.S. Department of Health and Human Services. GSK will work with Texas A&M on a $176 million deal.
NC biotech group hails formal dedication of the massive $1 billion Novartis plant in Holly Springs.
The U.S. Food and Drug Administration is taking Novartis CEO Joseph Jimenez to task with a warning letter that cites three of the company's manufacturing facilities for "significant violations" at the company's generics drug unit Sandoz.
- Fees grow faster than nest egg in NC employees' pension fund
- Raleigh nonprofit hopes 'pay what you want' pop-ups can help people get healthy meals
- Consumer Reports: Don't take out student loans you can't afford
- Cree (again) recalls LED lamps that get too hot
- NCSU scientists find iPhone, iPad security holes